Clinical Translational Research Oncology 2014;86:271–278 DOI: 10.1159/000360180
Received: January 29, 2014 Accepted: January 29, 2014 Published online: June 4, 2014
Urinary Podocyte Excretion and Proteinuria in Patients Treated with Antivascular Endothelial Growth Factor Therapy for Solid Tumor Malignancies Suzanne R. Hayman a Juan C. Calle b Aminah Jatoi c Iasmina M. Craici f Steven J. Wagner f Amy L. Weaver d Eddie L. Greene b Joseph P. Grande e Vesna D. Garovic b Divisions of a Hematology and b Nephrology and Hypertension, c Department of Medical Oncology, d Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, and e Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minn., and f Division of Nephrology and Hypertension, University of Mississippi, Jackson, Miss., USA
Abstract Background: Urinary podocyte excretion (podocyturia) may function as a more specific marker of ongoing glomerular damage. This study sought to analyze the relationship between proteinuria and podocyturia in cancer patients treated with antivascular endothelial growth factor (antiVEGF) agents. Methods: Thirty-seven patients treated with anti-VEGF medications were analyzed in a single-institution, cross-sectional study. Podocyte cultures were performed on random urine collections (50–100 ml), and podocytes were identified by positive podocin staining. The corresponding urine samples were analyzed for protein and creatinine (Cr) measurements. Results: Proteinuria ≥0.5 g/g Cr was found in 30% of the patients (median, 0.12; interquartile range,
© 2014 S. Karger AG, Basel 0030–2414/14/0866–0271$39.50/0 E-Mail [email protected] www.karger.com/ocl
0.04–0.86), and 62% had podocyturia. There was a significant difference in the amount of podocyturia between patients with proteinuria ≥0.5 g/g Cr and those with a value
Received: January 29, 2014 Accepted: January 29, 2014 Published online: June 4, 2014
Urinary Podocyte Excretion and Proteinuria in Patients Treated with Antivascular Endothelial Growth Factor Therapy for Solid Tumor Malignancies Suzanne R. Hayman a Juan C. Calle b Aminah Jatoi c Iasmina M. Craici f Steven J. Wagner f Amy L. Weaver d Eddie L. Greene b Joseph P. Grande e Vesna D. Garovic b Divisions of a Hematology and b Nephrology and Hypertension, c Department of Medical Oncology, d Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, and e Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minn., and f Division of Nephrology and Hypertension, University of Mississippi, Jackson, Miss., USA
Abstract Background: Urinary podocyte excretion (podocyturia) may function as a more specific marker of ongoing glomerular damage. This study sought to analyze the relationship between proteinuria and podocyturia in cancer patients treated with antivascular endothelial growth factor (antiVEGF) agents. Methods: Thirty-seven patients treated with anti-VEGF medications were analyzed in a single-institution, cross-sectional study. Podocyte cultures were performed on random urine collections (50–100 ml), and podocytes were identified by positive podocin staining. The corresponding urine samples were analyzed for protein and creatinine (Cr) measurements. Results: Proteinuria ≥0.5 g/g Cr was found in 30% of the patients (median, 0.12; interquartile range,
© 2014 S. Karger AG, Basel 0030–2414/14/0866–0271$39.50/0 E-Mail [email protected] www.karger.com/ocl
0.04–0.86), and 62% had podocyturia. There was a significant difference in the amount of podocyturia between patients with proteinuria ≥0.5 g/g Cr and those with a value
